422 related articles for article (PubMed ID: 27819059)
1. Resisting Resistance: Targeted Therapies in Lung Cancer.
Lin JJ; Shaw AT
Trends Cancer; 2016 Jul; 2(7):350-364. PubMed ID: 27819059
[TBL] [Abstract][Full Text] [Related]
2. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Suda K; Murakami I; Sakai K; Tomizawa K; Mizuuchi H; Sato K; Nishio K; Mitsudomi T
Lung Cancer; 2016 Jan; 91():36-40. PubMed ID: 26711932
[TBL] [Abstract][Full Text] [Related]
4. Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer.
Kuwano M; Sonoda K; Murakami Y; Watari K; Ono M
Pharmacol Ther; 2016 May; 161():97-110. PubMed ID: 27000770
[TBL] [Abstract][Full Text] [Related]
5. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
6. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Takeuchi S; Yano S
Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
9. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
10. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
12. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
16. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
17. Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.
Kanthala S; Pallerla S; Jois S
Future Oncol; 2015; 11(5):865-78. PubMed ID: 25757687
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
19. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
Lee DH
Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
[TBL] [Abstract][Full Text] [Related]
20. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]